Business context and reporting period
Entity mismatch: Although the request identifies Jasper Therapeutics, Inc., this filing is Amplitude Healthcare Acquisition Corporation’s Form 10-K. It reports the fiscal year ended December 31, 2020, not a Jasper Therapeutics filing or a standalone fourth-quarter report.
Amplitude was a pre-business-combination SPAC with no operating history or revenue. It was seeking a merger or similar transaction, with a stated focus on healthcare, life sciences and pharmaceutical services. Its business-combination deadline was November 22, 2021.
Financial results and liquidity
| Metric | FY 2020 | Prior period |
|---|---|---|
| Revenue | None | None |
| General and administrative expenses | $935,400 | $136,304 from inception on August 13, 2019 through December 31, 2019 |
| Trust-account interest income | $383,150 | $154,572 |
| Net income (loss) | $(590,701) | $2,043 |
| Cash used in operating activities | $(640,984) | $(367,473) from inception through year-end 2019 |
| Cash outside trust | $770,114 at year-end | $1,212,755 at year-end |
| Trust-account investments | $100,339,379 at year-end | $100,154,572 at year-end |
| Total liabilities | $3,769,451 | $3,611,364 |
The prior comparison covers less than a full year, so it is not directly comparable. The trust balance included $3.5 million of deferred underwriting fees payable only if a business combination closed. The company reported no long-term debt, and no working-capital loans were outstanding at year-end. Trust funds were invested in U.S. Treasury securities or qualifying Treasury money-market funds. The filing states there was no material market or interest-rate risk from these short-term holdings.
Material changes versus the prior period
Net results moved from a small profit in the 2019 inception period to a $590,701 loss in 2020, as operating expenses rose to $935,400. Cash outside the trust declined by $442,641 during 2020. The sponsor forfeited 375,000 founder shares after the underwriters’ over-allotment option expired unexercised, leaving 2.5 million founder shares outstanding.
Outlook, risks and unusual items
Management said available cash outside the trust was expected to fund operations through the November 22, 2021 deadline, but acknowledged estimates could prove insufficient and additional financing was not assured. The auditor and management cited substantial doubt about the company’s ability to continue as a going concern if it could not complete a business combination by that date; the financial statements were not adjusted for a potential liquidation.
If no combination closed by the deadline, the company was required to cease operations, redeem public shares from the trust and liquidate. Public warrants would expire worthless. The filing warns that creditor claims, bankruptcy proceedings or an inability of the sponsor to meet its indemnity obligations could reduce trust proceeds and investor recoveries.
Other key risks included competition for targets, redemption requests reducing cash available to close a deal, dependence on a single post-combination business, conflicts of interest and affiliated transactions, and COVID-19-related disruption. The sponsor and insiders held founder shares acquired for $25,000 in aggregate, creating potential incentives that may differ from public investors’ interests. Related-party expenses included $44,364 for office space during 2020 and $7,050 for consulting services. Mr. Kapoor received a monthly salary and was eligible for a $300,000 bonus contingent on closing a business combination.
Important facts for investors to verify
- Confirm the intended issuer: this filing is for Amplitude Healthcare Acquisition Corporation, not Jasper Therapeutics, Inc.
- Verify the reporting period and the limited comparability of 2019, which covers only the period from inception.
- Review the full audited financial statements and the going-concern disclosure, including the November 22, 2021 combination deadline.
- Check the trust-account balance, cash outside the trust, deferred underwriting fee, and any subsequent business-combination or financing filings.
- Check redemption limits in the governing documents: the filing’s narrative describes a 15% limit, while a financial-statement note describes a 10% threshold.